Lupin receives approval for Sulfamethoxazole and Trimethoprim Oral Suspension USP

Lupin Limited (Lupin), global pharmaceutical company, announced today that it has received approval for its Sulfamethoxazole and Trimethoprim Oral Suspension USP, 200 mg/40 mg per 5 mL, from the United States Food and Drug Administration, to market a generic equivalent of Bactrim Oral Suspension, 200 mg/40 mg per 5 mL, of Sun Pharmaceutical Industries, Inc.

Sulfamethoxazole and Trimethoprim Oral Suspension USP, 200 mg/40 mg per 5 mL, is indicated for the treatment and prevention of a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections), and certain type of pneumonia (pneumocystis-type).

Sulfamethoxazole and Trimethoprim Oral Suspension USP (RLD: Bactrim) had estimated annual sales of approximately USD 19 million in the U.S. (IQVIA MAT September 2020).

Shares of LUPIN LTD. was last trading in BSE at Rs.1000.60 as compared to the previous close of Rs. 1040.15. The total number of shares traded during the day was 3,48.530 and the deliverable quantity was 89,677 shares.

The stock hit an intraday high of Rs. 1040 and intraday low of Rs. 991.05.

Source : Equity Bulls

Keywords